CN108042517A - 用于治疗缺血性损伤的半胱胺和/或胱胺 - Google Patents

用于治疗缺血性损伤的半胱胺和/或胱胺 Download PDF

Info

Publication number
CN108042517A
CN108042517A CN201810067673.7A CN201810067673A CN108042517A CN 108042517 A CN108042517 A CN 108042517A CN 201810067673 A CN201810067673 A CN 201810067673A CN 108042517 A CN108042517 A CN 108042517A
Authority
CN
China
Prior art keywords
cysteamine
cystamine
acceptable salt
pharmaceutically acceptable
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810067673.7A
Other languages
English (en)
Chinese (zh)
Inventor
兰詹·多希尔
苏珊·A·菲利普斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN108042517A publication Critical patent/CN108042517A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201810067673.7A 2011-11-22 2012-11-21 用于治疗缺血性损伤的半胱胺和/或胱胺 Pending CN108042517A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563034P 2011-11-22 2011-11-22
US61/563,034 2011-11-22
CN201280057439.7A CN103974698A (zh) 2011-11-22 2012-11-21 用于治疗缺血性损伤的半胱胺和/或胱胺

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280057439.7A Division CN103974698A (zh) 2011-11-22 2012-11-21 用于治疗缺血性损伤的半胱胺和/或胱胺

Publications (1)

Publication Number Publication Date
CN108042517A true CN108042517A (zh) 2018-05-18

Family

ID=47297472

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810067673.7A Pending CN108042517A (zh) 2011-11-22 2012-11-21 用于治疗缺血性损伤的半胱胺和/或胱胺
CN201280057439.7A Pending CN103974698A (zh) 2011-11-22 2012-11-21 用于治疗缺血性损伤的半胱胺和/或胱胺

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280057439.7A Pending CN103974698A (zh) 2011-11-22 2012-11-21 用于治疗缺血性损伤的半胱胺和/或胱胺

Country Status (16)

Country Link
US (1) US20140322315A1 (https=)
EP (1) EP2782564B1 (https=)
JP (1) JP6411215B2 (https=)
KR (1) KR20140097132A (https=)
CN (2) CN108042517A (https=)
AU (1) AU2012340670B2 (https=)
BR (1) BR112014012167A2 (https=)
CA (1) CA2851387A1 (https=)
HK (1) HK1202440A1 (https=)
IL (1) IL232608A0 (https=)
MX (1) MX2014004469A (https=)
MY (1) MY165953A (https=)
RU (1) RU2638807C2 (https=)
SG (2) SG10201800159QA (https=)
WO (1) WO2013078335A1 (https=)
ZA (1) ZA201402290B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
EP3316877B1 (en) * 2015-07-02 2019-10-30 Horizon Orphan LLC Ado-resistant cysteamine analogs and uses thereof
CN106591461A (zh) * 2016-12-29 2017-04-26 天津协和华美医学诊断技术有限公司 一种检测遗传性易栓症相关基因群的检测试剂盒
EP3570826A4 (en) * 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
CA3050119A1 (en) * 2017-01-25 2018-08-02 Adare Pharmaceuticals, Inc. Cysteamine prodrugs
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN113484453B (zh) * 2021-07-07 2022-08-09 天津中医药大学 一种缺血性脑卒中预警方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306937A2 (en) * 1987-09-08 1989-03-15 The Green Cross Corporation Platelet agglutination-inhibiting agent
US6087398A (en) * 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
CN101822658A (zh) * 2004-05-03 2010-09-08 奥加生物药业(I.P.3)有限公司 半胱胺用于治疗高胆固醇血症和糖尿病并发症
CN101932238A (zh) * 2007-11-30 2010-12-29 加利福尼亚大学董事会 使用半胱胺制品治疗非酒精性脂肪性肝炎(nash)的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
FR2573077B1 (fr) * 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
JPH02243619A (ja) * 1989-03-15 1990-09-27 Green Cross Corp:The 抗血小板凝集剤
SK279476B6 (sk) 1989-05-17 1998-11-04 Pfizer Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
TW281670B (https=) 1993-09-02 1996-07-21 Hoffmann La Roche
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
AU1463997A (en) 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat
EP1024799A1 (en) 1997-10-24 2000-08-09 Warner-Lambert Company Method for treating disease-related or drug-induced dyskinesias
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
AU1808100A (en) 1998-10-28 2000-05-15 Vitaly V. Romanenko Electrodynamic particle size analyzer
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
SG149814A1 (en) * 2003-12-19 2009-02-27 Omega Bio Pharma Ip3 Ltd Compositions and methods for treating diabetes
RU2428192C1 (ru) * 2010-06-10 2011-09-10 Войсковая Часть 41598 Радиозащитное средство

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306937A2 (en) * 1987-09-08 1989-03-15 The Green Cross Corporation Platelet agglutination-inhibiting agent
US6087398A (en) * 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
CN101822658A (zh) * 2004-05-03 2010-09-08 奥加生物药业(I.P.3)有限公司 半胱胺用于治疗高胆固醇血症和糖尿病并发症
CN101932238A (zh) * 2007-11-30 2010-12-29 加利福尼亚大学董事会 使用半胱胺制品治疗非酒精性脂肪性肝炎(nash)的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DOHIL RANJAN ET AL.: "The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects", 《JOURNAL OF PEDIATRICS》 *
DONG-MYUNG SHIN ET AL.: "Cystamine prevents ischemia–reperfusion injury by inhibiting polyamination of RhoA", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 *
WANG TINGTING ET AL.: "N-acetylcysteine and allopurinol synergistically enhance cardiac adiponectin content and reduce myocardial reperfusion injury in diabetic rats", 《PLOS ONE》 *
ZHIXIN GUO ET AL.: "Effect of N-acetylcysteine on plasma adiponectin and renal adiponectin receptors in streptozotocin-induced diabetic rats", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 *

Also Published As

Publication number Publication date
RU2014125282A (ru) 2015-12-27
CN103974698A (zh) 2014-08-06
RU2638807C2 (ru) 2017-12-15
HK1202440A1 (zh) 2015-10-02
ZA201402290B (en) 2017-06-28
MX2014004469A (es) 2014-08-01
AU2012340670A1 (en) 2014-04-17
CA2851387A1 (en) 2013-05-30
SG11201402472QA (en) 2014-06-27
JP6411215B2 (ja) 2018-10-24
US20140322315A1 (en) 2014-10-30
JP2014533701A (ja) 2014-12-15
IL232608A0 (en) 2014-06-30
EP2782564B1 (en) 2019-01-09
BR112014012167A2 (pt) 2017-05-30
SG10201800159QA (en) 2018-02-27
EP2782564A1 (en) 2014-10-01
KR20140097132A (ko) 2014-08-06
AU2012340670B2 (en) 2016-12-22
WO2013078335A1 (en) 2013-05-30
MY165953A (en) 2018-05-18

Similar Documents

Publication Publication Date Title
KR910004572B1 (ko) 경구용 당뇨병 치료제 제형의 제조방법
AU2012340670B2 (en) Cysteamine and/or cystamine for treating ischemic injury
US8329693B2 (en) Method for the prevention of thromboembolic disorders
JP5908527B2 (ja) 慢性虚血における亜硝酸塩の使用
KR20190035776A (ko) 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
CN108472275A (zh) 治疗缺血性中风的组合物及方法
CN110167538B (zh) 用于治疗心血管疾病的方法
US11612615B2 (en) Combined administration of cysteine-aspartic protease inhibitors with P2Y12 receptor antagonists protects the heart against myocardial infarction
JP2010053144A (ja) 血管形成的に有効なｆｇｆ−２の単位用量および使用方法
JP2010504911A (ja) 急速に崩壊する、トロンビン受容体アンタゴニストの凍結乾燥経口処方物
JP2014533697A (ja) デフェリプロンを用いた処置方法
JP2006514665A (ja) 慢性心不全および／または上昇したコレステロールレベルを処置するための方法
US20150079183A1 (en) Lercanidipine Hydrochloride and Losartan Potassium Compound Preparation and Preparation Method Thereof
JP2002524420A (ja) 脈管形成に有効な単位用量のｆｇｆ−２および使用方法
EP4511040A1 (en) Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock
CN117257803A (zh) 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用
JP2003527420A (ja) 鬱血性心不全の治療方法
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
JP2024503377A (ja) バダデュスタットを使用した治療方法
US20220096597A1 (en) Cardio-protective effect of vasoconstriction-inhibiting factor (vif)
TW202304439A (zh) 治療急性缺血性中風的方法
CN120603579A (zh) 新型溶液
HK1107000B (en) A method for the prevention of thromboembolic disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180518

WD01 Invention patent application deemed withdrawn after publication